ALERT- NEWS---SBIO Launches New Product
Synbiotics Corp. Launches Product
SAN DIEGO--(BW HealthWire)--Dec. 1, 1997--Synbiotics Corp.
(NASDAQ:SBIO) Monday announced that it has received regulatory
approval to market D-TEC CB, a proprietary diagnostic test for canine
brucellosis.
Synbiotics' customers will begin receiving shipments this week.
Brucellosis is an infection in dogs caused by the bacterial organism "Brucella canis." It is of special concern to veterinarians and dog breeders because of its impact on canine reproduction. Symptoms of the disease can include impotence and sterility in the male, infertility in females and loss of unborn puppies.
The American Kennel Club (AKC) recommends that all dogs used for
breeding have two negative tests, 30 days apart. While the total number of dog breedings is not known, each year there are approximately 750,000 purebred dog litters born to the approximately 22 million purebred dogs in the United States.
According to Ken Cohen, Synbiotics president and chief executive officer, "D-TEC CB represents a substantial opportunity for Synbiotics. It complements our market-leading position in products and services for canine reproduction. It's something our customers have been asking for, and we are manufacturing with existing resources in San Diego."
Synbiotics previously marketed another product also known as D-TEC CB
which was manufactured by a third party. The new product, however, was developed and will be manufactured by Synbiotics.
Synbiotics develops, manufactures and markets veterinary diagnostics,
vaccines and related animal-health products.
For more information, please visit Synbiotics' Web site at
stockprofiles.com .
With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including patent litigation relating to heartworm diagnotics, competition from larger companies, reliance on third-party manufacturers and distributors, possible technology
improvements by others, the ability to assimilate acquired businesses, the seasonality of major portions of the company's business and other risks set forth in the company's filings with the Securities and Exchange Commission, particularly Form 10-KSB filed for the year ended Dec. 31, 1996. Actual results may differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of the release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT: Synbiotics Corp., San Diego
Michael K. Green, 619/451-3771
mikeg@synbiotics.com
Kenneth M. Cohen, 619/451-3771
kenc@synbiotics.com
or
Financial Relations Board
Fiona Ross, 310/442-0599
Kathy Brunson, 312/266-7800 |
